In vivo molecular imaging analysis of a Nasal vaccine that induces protective immunity against botulism in nonhuman primates

Journal of Immunology

Volumn 185, Issue 9, 2010, Pages 5436-5443

  Yuki, Yoshikazu ^a   Nochi, Tomonori ^a   Harada, Norihiro ^b   Katakai, Yuko ^c   Shibata, Hiroaki ^c   Mejima, Mio ^a   Kohda, Tomoko ^d   Tokuhara, Daisuke ^a   Kurokawa, Shiho ^a   Takahashi, Yuko ^a   Ono, Fumiko ^c   Kozaki, Shunji ^d   Terao, Keiji ^c   Tsukada, Hideo ^b   Kiyono, Hiroshi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b CENTRAL RESEARCH LABORATORY   (Japan)

^c NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^d Osaka Prefecture University   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINIUM VACCINE; BOTULINUM TOXIN A; FLUORINE 18; INDIUM 111; UNCLASSIFIED DRUG; VACCINE; BACTERIAL VACCINE; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN DETECTION; ARTICLE; BOTULISM; CLOSTRIDIUM BOTULINUM TYPE A; DRUG ACCUMULATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; FEMALE; IMAGE ANALYSIS; IMMUNE RESPONSE; IMMUNITY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MOLECULAR IMAGING; MOUSE; NONHUMAN; OLFACTORY BULB; PASSIVE IMMUNIZATION; POSITRON EMISSION TOMOGRAPHY; PRIMATE; PRIORITY JOURNAL; RADIOACTIVITY; ANIMAL; BAGG ALBINO MOUSE; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; MACACA; METHODOLOGY; SCINTISCANNING;

ADMINISTRATION, INTRANASAL; ANIMALS; BACTERIAL VACCINES; BOTULINUM TOXIN TYPE A; BOTULISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORODEOXYGLUCOSE F18; MACACA FASCICULARIS; MICE; MICE, INBRED BALB C; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 78149481040     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1001789     Document Type: Article

References (29)

1. Yuki, Y., and H. Kiyono. 2009. Mucosal vaccines: novel advances in technology and delivery. Expert Rev. Vaccines 8:1083-1097.
2. Mutsch, M., W. Zhou, P. Rhodes, M. Bopp, R. T. Chen, T. Linder, C. Spyr, and R. Steffen. 2004. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350:896-903.
3. van Ginkel, F. W., R. J. Jackson, Y. Yuki, and J. R. McGhee. 2000. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J. Immunol. 165:4778-4782.
4. Illum, L. 2003. Nasal drug delivery-possibilities, problems and solutions. J. Control. Release 87:187-198.
5. Staud, F., M. Nishikawa, K. Morimoto, Y. Takakura, and M. Hashida. 1999. Disposition of radioactivity after injection of liver-targeted proteins labeled with 111In or 125I. Effect of labeling on distribution and excretion of radioactivity in rats. J. Pharm. Sci. 88:577-585.
6. Gross, S., S. T. Gammon, B. L. Moss, D. Rauch, J. Harding, J. W. Heinecke, L. Ratner, and D. Piwnica-Worms. 2009. Bioluminescence imaging of myeloperoxidase activity in vivo. Nat. Med. 15:455-461.
7. Muramatsu, S., T. Okuno, Y. Suzuki, T. Nakayama, T. Kakiuchi, N. Takino, A. Iida, F. Ono, K. Terao, N. Inoue, et al. 2009. Multitracer assessment of dopamine function after transplantation of embryonic stem cell-derived neural stem cells in a primate model of Parkinson's disease. Synapse 63:541-548.
8. Brooks, D. J. 2008. The role of structural and functional imaging in parkinsonian states with a description of PET technology. Semin. Neurol. 28:435-445.
9. Vallabhajosula, S. 2007. (18) F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization. Semin. Nucl. Med. 37:400-419.
10. May, A. 2009. New insights into headache: an update on functional and structural imaging findings. Nat. Rev. Neurol. 5:199-209.
11. Yagle, K. J., J. F. Eary, J. F. Tait, J. R. Grierson, J. M. Link, B. Lewellen, D. F. Gibson, and K. A. Krohn. 2005. Evaluation of 18F-annexin V as a PET imaging agent in an animal model of apoptosis. J. Nucl. Med. 46:658-666.
12. Park, J. B., and L. L. Simpson. 2003. Inhalational poisoning by botulinum toxin and inhalation vaccination with its heavy-chain component. Infect. Immun. 71:1147-1154.
13. Boles, J., M. West, V. Montgomery, R. Tammariello, M. L. Pitt, P. Gibbs, L. Smith, and R. D. LeClaire. 2006. Recombinant C fragment of botulinum neurotoxin B serotype (rBoNTB (HC)) immune response and protection in the rhesus monkey. Toxicon 47:877-884.
14. Fujihashi, K., H. F. Staats, S. Kozaki, and D. W. Pascual. 2007. Mucosal vaccine development for botulinum intoxication. Expert Rev. Vaccines 6:35-45.
15. Sakaguchi, G. 1982. Clostridium botulinum toxins. Pharmacol. Ther. 19:165-194.
16. Kondo, H., T. Shimizu, M. Kubonoya, N. Izumi, M. Takahashi, and G. Sakaguchi. 1984. Titration of botulinum toxins for lethal toxicity by intravenous injection into mice. Jpn. J. Med. Sci. Biol. 37:131-135.
17. Haka, M. S., and M. R. Kilbourn. 1989. Synthesis and regional mouse brain distribution of [11C]nisoxetine, a norepinephrine uptake inhibitor. Int. J. Rad. Appl. Instrum. B 16:771-774.
18. 18F]SFB) for protein labeling. J. Labelled Comp. Radiopharm. 51:68-71.
19. Michel, R. B., P. M. Andrews, M. E. Castillo, and M. J. Mattes. 2005. In vitro cytotoxicity of carcinoma cells with 111In-labeled antibodies to HER-2. Mol. Cancer Ther. 4:927-937.
20. Mizuta, T., K. Kitamura, H. Iwata, Y. Yamagishi, A. Ohtani, K. Tanaka, and Y. Inoue. 2008. Performance evaluation of a high-sensitivity large-aperture small-animal PET scanner: ClairvivoPET. Ann. Nucl. Med. 22:447-455.
21. Uchida, H., T. Okamoto, T. Ohmura, N. Shimizu, N. Satoh, T. Koike, and T. Yamashita. 2004. A compact planar poitron imaging system. Nucl. Instrum. Methods Phys. Res. A 516:564-574.
22. Watanabe, M., H. Okada, K. Shumizu, T. Omura, E. Yoshikawa, T. Kosugi, S. Mori, and T. Yamashita. 1997. A high resolution animal PET scanner using compact PS-PMT detectors. IEEE Trans. Nucl. Sci. 44:1277-1282.
23. Hagiwara, Y., Y. I. Kawamura, K. Kataoka, B. Rahima, R. J. Jackson, K. Komase, T. Dohi, P. N. Boyaka, Y. Takeda, H. Kiyono, et al. 2006. A second generation of double mutant cholera toxin adjuvants: enhanced immunity without intracellular trafficking. J. Immunol. 177:3045-3054.
24. Franano, F. N., W. B. Edwards, M. J. Welch, and J. R. Duncan. 1994. Metabolism of receptor targeted 111In-DTPA-glycoproteins: identification of 111In-DTPA-epsilon-lysine as the primary metabolic and excretory product. Nucl. Med. Biol. 21:1023-1034.
25. Grant, F. D., F. H. Fahey, A. B. Packard, R. T. Davis, A. Alavi, and S. T. Treves. 2008. Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J. Nucl. Med. 49:68-78.
26. Hussain, A., J. Faraj, Y. Aramaki, and J. E. Truelove. 1985. Hydrolysis of leucine enkephalin in the nasal cavity of the rat-a possible factor in the low bioavailability of nasally administered peptides. Biochem. Biophys. Res. Commun. 133:923-928.
27. Jørgensen, L., and E. Bechgaard. 1994. Intranasal permeation of thyrotropinreleasing hormone: in vitro study of permeation and enzymatic degradation. Int. J. Pharm. 107:231-237.
28. Ravichandran, E., F. H. Al-Saleem, D. M. Ancharski, M. D. Elias, A. K. Singh, M. Shamim, Y. Gong, and L. L. Simpson. 2007. Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect. Immun. 75:3043-3054.
29. Gill, D. M. 1982. Bacterial toxins: a table of lethal amounts. Microbiol. Rev. 46:86-94.